Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Alternative Donor Transplantation Poster II

Sunday, December 7, 2008: 6:00 PM-8:00 PM
Hall A (Moscone Center)
Favorable Leukemia-Free Survival (LFS) for Adults and Children Undergoing Myeloablative Umbilical Cord Blood (UCB) Transplantation with Cyclophosphamide (CY), Fludarabine (FLU) and Total Body Irradiation (TBI): A Single Center Analysis of 194 Patients

Claudio Brunstein, MD, PhD1, Daniel Weisdorf1*, Todd DeFor2*, Jeffrey S. Miller, MD1, Philip B. McGlave1*, Bruce R. Blazar, MD1 and John E. Wagner, MD3

1University of Minnesota, Minneapolis, MN
2Cancer Center Biostatistics, University of Minnesota, Minneapolis, MN
3Pediatric Hematology, Oncology, University of Minnesota, Minneapolis, MN

High Rate of Second Malignancies after Reduced Intensity Double Cord Blood Transplants in AdultsClinically Relevant Abstract

Karen K Ballen, MD1, Corey Cutler, MD2*, Beow Y Yeap, Sc.D3*, Steven L McAfee, MD4*, Bimalangshu R Dey, MD4, Eyal C Attar, MD4, Richard L Haspel, MD5*, Deborah Liney, BA2*, John Koreth, MBBS, DPhil2, Vincent Ho, MD2, Edwin P Alyea III, MD2*, Robert J Soiffer, MD2*, Thomas R Spitzer, MD4* and Joseph H Antin, MD2

1Massachusetts General Hospital, Boston, MA
2Hematologic Malignancy, Dana-Farber Cancer Institute, Boston, MA
3Biostatistics Center, Massachusetts General Hospital, Boston, MA
4Hematology/Oncology, Massachusetts General Hospital, Boston, MA
5Pathology, Beth Israel Deaconess Medical Center, Boston, MA

Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Indolent Non-Hodgkin Lymphoma: Interim Analysis of a Phase II StudyClinically Relevant Abstract

Wolfgang A Bethge, MD1*, Thoralf Lange, MD2*, Stephanie von Harsdorf, MD3*, Martin Bornhauser, MD4*, Birgit Federmann, MD1*, Michael Stadler, MD5*, Lutz Uharek6*, Stefan Knop, MD7*, Gerald Wulf, MD8, Helmut Dittmann, MD9*, Christoph Faul, MD1*, Wichard Vogel, MD1*, Lothar Kanz, MD10 and Donald Bunjes, MD3*

1Hematology & Oncology, Medical Center University of Tuebingen, Tuebingen, Germany
2Hematology & Oncology, Medical Center University of Leipzig, Leipzig, Germany
3Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
4University Hospital Dresden, Dresden, Germany
5Hematology & Oncology, Medical Center University of Hannover, Hannover, Germany
6Medical Clinic III - Hematology and Oncology, Charité University Medicine Berlin, Germany
7Hematology & Oncology, Medical Center University of Wuerzburg, Wuerzburg, Germany
8Hematology & Oncology, Medical Center University of Goettingen, Goettingen, Germany
9Nuclear Medicine, University of Tuebingen Medical Center, Tuebingen, Germany
10Hematology and Oncology, Eberhard Karls University, Tuebingen, Germany

Prospective Phase II Study of Biologic Assignment One Vs Two Unit Umbilical Cord Blood Transplant (UCBT) in the Reduced-Intensity Conditioning SettingClinically Relevant Abstract

Tamila L. Kindwall-Keller, DO1, Yael Hegerfeldt, MD1*, Pingfu Fu, PhD2*, Hillard M. Lazarus, MD1*, Brenda W. Cooper, MD1*, Paul Barr, MD1*, Stanton L. Gerson, MD1*, Howard Meyerson, MD3*, Sally Erinc, RN4*, Richard J. Creger, PharmD1*, Laura Fanning, PhD5*, Nicholas Greco, PhD5*, Peter Haviernik, PhD5*, Mathew Lesniewski, PhD5* and Mary J. Laughlin, MD6

1Department of Internal Medicine, University Hospitals of Cleveland, Case Medical Center, Cleveland, OH
2Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH
3Department of Pathology, University Hospitals of Cleveland, Case Medical Center, Cleveland, OH
4Blood and Marrow Transplant Program, University Hospitals of Cleveland, Case Medical Center, Cleveland, OH
5Internal Medicne, Hematology/Oncology, Case Western Reserve University, Cleveland, OH
6University Hospitals of Cleveland, Case Medical Center, Cleveland, OH

Direct Intra-Bone Cord-Blood Transplantation Overcomes the Problem of Graft Failure Even When Low Numbers of HLA-Mismatched Cord-Blood Cells Are Transplanted, Thus Leading to the Possibility of Use of This Technique in a Large Number of PatientsClinically Relevant Abstract

Francesco Frassoni, MD1*, Franca Fagioli, MD2*, Marina Podestà, BiolSci1*, Francesca Gualandi, MD3*, Massimo Berger, MD2*, Francesca Nesi, MD2*, Annamaria Raiola, MD3*, Adalberto Ibatici, MD1*, Marco Gobbi, MD4*, Myriam Labopin, MD5* and Andrea Bacigalupo, MD6

1Stem Cell and Cell Therapy Centre, San Martino Hospital, Genoa 16132, Italy
2Stem Cell Transplantation and Cellular Therapy Unit, Regina Margherita Children's Hospital, Torino 10126, Italy
3Division of Hematology and Bone Marrow Transplant Unit, San Martino Hospital, Genoa, 16132
4Clinical hematology, University of Genova Italy, Genova, Italy
5Hopital Saint-Antoine, Université Pierre et Marie Curie Paris 6, Paris 75571, France
6Hem-Onc, Ospedale S. Martino, Genova, Italy

Haploidentical Allogeneic Hematopoietic Cell Transplantation in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Interim Analysis of a Phase I/II Study

Birgit Federmann, MD1*, Martin Bornhauser, MD2*, Dietrich W. Beelen, MD3*, Gernot Stuhler, MD4*, Lambros Kordelas, MD3*, Rainer Schwerdtfeger, MD5, Matthias Stelljes, MD6*, Christoph Faul, MD1*, Wichard Vogel, MD1*, Rupert Handgretinger, MD7*, Lothar Kanz, MD1 and Wolfgang A. Bethge, MD1*

1Hematology & Oncology, University of Tuebingen Medical Center, Tuebingen, Germany
2Internal Medicine I, University Hospital Dresden, Dresden, Germany
3Department of Bone Marrow Transplantation, University Hospital Essen, Essen, Germany
4Hematology & Oncology, University of Wuerzburg Medical Center, Wuerzburg, Germany
5DKD Wiesbaden, Germany
6Hematology & Oncology, University of Muenster Medical Center, Muenster, Germany
7Hematology & Oncology, Children's University Hospital, Tubingen, Germany

Single Institute Analysis of Reduced Intensity Cord Blood Transplantation from Unrelated Donors for Adults with Advanced Lymphoid MalignanciesClinically Relevant Abstract

Atsushi Wake, MD1*, Naoyuki Uchida, MD1, Kazuya Ishiwata1*, Shinsuke Takagi1*, Masanori Tsuji1*, Hisashi Yamamoto1*, Mayumi Yoshimi, MD1*, Madoka Narita1*, Kimiko Sagawa1*, Hideki Araoka2*, Daisuke Kato1*, Naofumi Matsuno1*, Kazuhiro Masuoka1*, Akiko Yoneyama2*, Shigeyoshi Makino3* and Shuichi Taniguchi, MD, PhD1*

1Department of Hematology, Toranomon Hospital, Tokyo, Japan
2Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan
3Department of Transfusion Medicine, Toranomon Hospital, Tokyo, Japan

Encoraging Results after Alternative Donor Transplantation for Myelodysplastic SyndromeClinically Relevant Abstract

Franco Locatelli, MD, PhD1*, Adrienne Moreno-Madureira, MD2*, Pierre Teira, MD2*, Mary Eapen, MBBS3, Mei-Jie Zhang, PhD3*, Stella M. Davies, MBBS, PhD4, Alessandra Picardi, MD5*, Ann E Woolfrey, MD6*, Ka Wah Chan, MBBS7, Gerard Socie, MD8*, Ajay J. Vora9, Yves Bertrand10*, Joanne Kurtzberg, MD11, Carmen Bonfim, MD12*, Eliane Gluckman, MD8, Charlotte M Niemeyer, MD, PhD13 and Vanderson Rocha, MD, PhD14

1Oncoematologia Pediatrica, Charles University, University Hospital Motol, Pavia, Italy
2Hopital Saint Louis, Paris, France
3Medical College of Wisconsin, Milwaukee, WI
4Medical Ctr., Cincinnati Children's Hosp. and, Cincinnati, OH
5Universita di Roma Tor Vergata, Rome, Italy
6Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
7Texas Transplant Institute, San Antonio, TX
8Hopital Saint-Louis, Paris, France
9Dept. of Pediatric Hematology, The Children's Hospital, Sheffield, United Kingdom
10CHU Lyon, Lyon, France
11Duke University Medical Center, Durham, NC
12Federal University of Parana, Curitiba, Brazil
13Universitaets-Kinderklinik, Freiburg, Germany
14BMT unit, Hopital Saint Louis APHP and University of Paris VII, Paris, France

Interest of Non-Myeloablative Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: A Multicenter Retrospective Study

Steven Le Gouill, MD, PhD1*, Nikolaus Kroeger, MD2, Nathalie Dhedin3*, Arnon Nagler4, Krimo Bouabdallah5*, Ibrahim Yakoub-Agha, MD, PhD6, Claude-Eric Bulabois7*, Agnes Buzyn8*, Bernard Rio9*, Marie-Pierre Moles10*, Avichai Shimoni11*, Thierry Guillaume12*, Noel Milpied, MD13*, Lucie Planche14*, Jean-Luc Harousseau, MD15* and Mohamad Mohty, MD, PhD16

1Haematology, CHU Nantes, Nantes, France
2Martinistr. 52, University Hospital of Hamburg, Hamburg, Germany
3Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, Paris, France
4Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
5Hematology, CHU de Bordeaux, Bordeaux, France
6Maladies du Sang, UAM Allo-CSH - EA2686, Lille, France
7Hematology department, CHU Grenoble, Grenoble, France
8Hopital Necker, Paris, France
9Département d'Hématologie et d'Oncologie Médicale, Hôtel Dieu, Paris, France
10Hematology department, CHU d'Angers, Angers, France
11Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel
12Hematology, CHU Hotel-Dieu, Nantes, France
13Hématologie, CHU de Bordeaux, Bordeaux, France
14Cellule de Promotion à la recherche clinique, CHU Hotel-Dieu, Nantes, France
15Département d'Hématologie, Hôpital Hôtel Dieu, Nantes, France
16Hematology Dept., CHU de Nantes, Nantes, France

Stem Cell Transplantation in Elderly Patients with Acute Lymphoblastic Leukemia (ALL) in First Complete Remission (CR1)

Renate Arnold1, Dietrich Beelen2*, Martin Bornhaeuser3*, Donald Bunjes, MD4*, Juergen Finke5, Nikolaus Kroeger, MD6, Michael Stadler, MD7*, Matthias Stelljes8*, Nicola Goekbuget, MD9 and Dieter Hoelzer, MD, PhD10

1Hematology and Oncology, Charite - Universitaetsmedizin Berlin, CVK, Berlin, Germany
2Department of Bone Marrow Transplantation, University Hospital Essen
3Medical Clinic I, University Hospital, Dresden, Germany
4Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
5Dept. of Hematology/Oncology, University Medical Center Freiburg, Germany
6Martinistr. 52, University Hospital of Hamburg, Hamburg, Germany
7Hematology & Oncology, Medical Center University of Hannover, Hannover, Germany
8Department of Hematology/Oncology, University of Muenster, Münster, Germany
9Medical Department II, J.W.Goethe University, Frankfurt, Germany
10J.W. Goethe University Hospital, Frankfurt/M, Germany

Unrelated Cord Blood Transplantation after Nonmyeloablative Conditioning : Single Institutional Retrospective Comparison with Bone Marrow or Peripheral Blood Stem-Cell TransplantsClinically Relevant Abstract

Koichiro Kobayashi, MD, Yoshinobu Maeda, MD*, Hisakazu Nishimori, MD*, Haruko Sugiyama, MD*, Kazutoshi Aoyama, MD*, Tomoko Kikuchi, MD*, Noriko Namba, MD*, Shiro Kubonishi, MD*, Masami Niiya, MD*, Katsuji Shinagawa, MD*, Kazuma Ikeda, MD and Mitsune Tanimoto, MD

Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan

Donor Characteristics Affecting Graft Failure and Survival after Unrelated Donor Transplantation with Reduced Intensity Conditioning Regimens (RIC) for Hematologic MalignanciesClinically Relevant Abstract

Jakob R. Passweg, MD, MS1, Fangyu Kan, MS, MA2*, Mei-Jie Zhang, PhD3*, Vanderson Rocha, MD, PhD4*, Luis M. Isola, MD5*, Adrian P. Gee, PhD6, John Gibson, MBBS, FRACP, FRCPA7, Hillard M. Lazarus, MD8, Mary J. Laughlin, MD9, Alison Loren, MD, MS10*, David Marks, MD, PhD11, Alois Gratwohl12 and Mary Eapen, MBBS3

1Hopitaux Universitaires de Geneve, Geneve, Switzerland
2National Marrow Donor Program, Minneapolis, MN
3Medical College of Wisconsin, Milwaukee, WI
4Hopital Saint Louis, Paris, France
5Mount Sinai Medical Center, New York, NY
6Baylor College of Medicine, Houston, TX
7Royal Prince Alfred Hospital, Camperdown, Australia
8University Hospitals Case Medical Center, Cleveland, OH
9University Hospitals of Cleveland, Case Medical Center, Cleveland, OH
10Hospital of the University of Pennsylvania, Philadelphia, PA
11United Bristol Healthcare Trust., Bristol, United Kingdom
12University Hospital Basel, Basel, Switzerland

Cord Blood (CB) Unit Mononuclear Cell (MNC) Dose: Effect on Transplantation Outcome and Relevance to Processing Method and CBU Selection

Andromachi Scaradavou, Cladd Stevens, MD*, Ludy Dobrila, PhD*, Tracy Zhu*, Shanlong Jiang*, Diana Daniels*, Patricia E Taylor*, Dorothy Sung*, Maria S Albano, PhD and Pablo Rubinstein, MD

National Cord Blood Program, New York Blood Center, New York, NY

Reduced-Intensity Unrelated Cord Blood Transplantation in Adult – a Single Center Analysis of  318 TransplantsClinically Relevant Abstract

Shuichi Taniguchi, MD, PhD1, Atsushi Wake1*, Kazuhiro Masuoka1*, Naoyuki Uchida1*, Naofumi Matsuno1*, Shinsuke Takagi1*, Hisashi Yamamoto1*, Masanori Tsuji1*, Kazuya Ishiwata1*, Yoshimi Mayumi1*, Kimiko Sagawa1*, Madoka Narita1*, Shigeyoshi Makino2*, Hideki Araoka3* and Akiko Yoneyama3*

1Department of Hematology, Toranomon Hospital, Tokyo, Japan
2Department of Transfusion Medicine, Toranomon Hospital, Tokyo, Japan
3Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan

Improved Outcome for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Poor Risk Cytogenetics – Result from An Analysis on 172 Patients Receiving FLAMSA-RIC Conditioning for Allogeneic Stem Cell Transplantatioin (SCT)Clinically Relevant Abstract

Tim Pfeiffer1*, Michael Schleuning2*, Matthias Eder, MD3*, Marta Krejci4*, Karin Kolbe, MD5*, Christof Scheid6, Renate Arnold, MD, PhD7*, Armin Gerbitz, MD8, Donald Bunjes, MD9*, Ernst Holler, PhD10*, Gesine Bug11*, Maximillian Christopeit12*, Hildegard Greinix13, Matthias Stelljes14*, Wolfgang A. Bethge, MD15*, Daniel V Oruzio1*, Elke Dammann3*, Margret Rothmayer16*, Ralf Meyer5*, Jiri Mayer, MD4*, Rainer Schwerdtfeger, MD17, Arnold Ganser3*, Hans-Jochem Kolb16* and Christoph Schmid1*

12. Medizinische Klinik, Zentralklinikum Augsburg, Augsburg, Germany
2Centre for hematopoietic cell transplantation, German Diagnostic Clinic, Wiesbaden, Germany
3Hematology and Oncology, Hannover Medical School, Hannover, Germany
4Masaryk University Hospital, Brno, Czech Republic
5University Mainz, Mainz, Germany
6I. Dept. of Medicine, University of Cologne, Cologne, Germany
7Department of Hematology and Oncology, Charité - University Medicine Berlin, Campus Virchow-Klinikum, Berlin, Germany
8Charite Zentrum für Tumormedizin, Medizinische Klinik mit Schwerpunkt, Berlin, Germany
9Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
10Klinikum der Universitat Regensburg, Regensburg, Germany
11Hematology/Oncology, University Hospital, Frankfurt, Germany
12State Center of Gene and Cell Therapy, Martin-Luther-university Halle/Wittenberg, Halle, Germany
13Internal Medicine I, BMT, Medical University of Vienna, Vienna, Austria
14Department of Hematology/Oncology, University of Muenster, Münster, Germany
15Hematology & Oncology, University of Tuebingen Medical Center, Tuebingen, Germany
16Transplantation, Dept. Medicine III, University of Munich, Muenchen, Germany
17DKD Wiesbaden, Germany

Double Cord Blood Cell (CBC) Hematopoietic Stem Cell Transplantation after Standard or Reduced Intensity Conditioning: Report of the SFGM-TC RegistryClinically Relevant Abstract

Mauricette Michallet, MD, PhD1, Quoc Hung Le, MD1*, Marie Robin, MD2*, Nathalie Fegueux, MD3*, Sabine Furst4*, Mohamad Mohty, MD, PhD5, Eric Deconinck6*, Loic Fouillard7*, Pierre Bordigoni8, Bernard Rio9*, Anne Sirvent10*, Marc Renaud8*, Nathalie Dhedin11*, Reza Tabrizi12, Sebastien Maury13*, Mohamad Sobh, PhD1*, Nicole Raus1*, Federico Garnier14*, Marie-Lorraine Balere15*, Vanderson Rocha, MD, PhD16, Didier Blaise, MD17 and Helene Labussiere1*

1Hematology, Hopital Edouard Herriot, Lyon, Cedex 03, France
2Bone Marrow Transplantation, Saint -Louis Hospital, Paris, France
3Service Oncologie et Hématologie, Hôpital Lapeyronie, Montpellier, France
4Unité de Transplantation et de Thérapie Cellulaire (UTTC), Institut Paoli-Calmettes, Marseille, France., Marseille, France
5Hematology Dept., CHU de Nantes, Nantes, France
6European APL group, Bobigny, France
7Hematology, AP-HP Hopital Saint-Antoine, Paris, France
8Société Française de Greffe de Moelle et de Therapie Cellulaire, Sfgmtc, France
9Département d'Hématologie et d'Oncologie Médicale, Hôtel Dieu, Paris, France
10Hôpital de l'Archet 1, Nice, France
11Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, Paris, France
12Hematology, CHU de Bordeaux, Bordeaux, France
13Hematology, Hôpital Henri Mondor
14French Network of Cord Blood Banks, Paris, France
15Agence de Biomedecine, Paris, France
16BMT unit, Hopital Saint Louis APHP and University of Paris VII, Paris, France
17Institut Paoli Calmettes, Marseille, France

Rapid NKG2D Reconstitution on NK Cells Possibly Plays a Major Role in the Development of Graft-Versus-Leukemia Effect in the Early Period after Unrelated Cord Blood Transplantation

Zimin Sun*, Jie Chen*, Huilan Liu*, Xingbing Wang*, Liangquan Geng*, Wen Yao* and Juan Tong*

Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China

Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study

Bertram Glass, MD1*, Justin Hasenkamp, MD2*, Anke Görlitz3*, Peter Dreger, MD4*, Jörg Schubert, MD5*, Gerald Wulf, MD2, Maike Nickelsen, MD1*, Lorenz H. Truemper, MD2 and Norbert Schmitz, MD, PhD1

1Hematology and Stem Cell Transplantation, ASKLEPIOS Klinik St. Georg, Hamburg, Germany
2Hematology and Oncology, University Medicine Göttingen, Göttingen, Germany
3Ifs, University Medicine Göttingen, Göttingen, Germany
4Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany
5Medizinische Klinik 1, Universitätsklinik des Saarlandes, Homburg, Germany

Single Donor 4/6 Matched Banked Unrelated Cord Blood Is An Effective Graft Source for Children Undergoing Myeloablative Transplantation for Malignant and Nonmalignant Disorders: Single Center Analysis of 318 PatientsClinically Relevant Abstract

Vinod K. Prasad, MBBS, MD, MRCP1*, Premjit Gill, MBChB1*, Richard Vinesett, BS1*, Suhag H Parikh, MD1*, Paul Szabolcs, MD1*, Timothy A Driscoll, MD1*, Kristin M Page, MD2*, Susan Wood, PNP1*, Deborah Semmel, FNP1*, Paul L Martin, MD, PhD1* and Joanne Kurtzberg, MD1

1Division of Blood and Marrow Transplantation, Department of Pediatrics, Duke University Medical Center, Durham, NC
2Division of Pediatric Hematology Oncolog, Duke University Medical Center, Durham, NC

Engraftment Syndrome Following Unrelated Cord Blood Transplant in Pediatric PatientsClinically Relevant Abstract

Jennifer Domm, MD, Li Wang*, Cassie Calder*, Becky Manes* and Haydar Frangoul

Vanderbilt University Medical Center, Nashville, TN

*signifies non-member of ASH